Skip to Content
Merck
CN
All Photos(1)

Key Documents

Safety Information

SML0359

Sigma-Aldrich

Norgestimate

≥97% (HPLC)

Synonym(s):

(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, Dexnorgestrel acetime

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H31NO3
CAS Number:
Molecular Weight:
369.50
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77

Assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL (clear solution)

storage temp.

−20°C

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C

InChI

1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1

InChI key

KIQQMECNKUGGKA-NMYWJIRASA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Norgestimate is a synthetic progestin used in combination with estrogens as a contraceptive.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazardExclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jason D Vescovi et al.
Contraception, 77(2), 97-104 (2008-01-30)
We examined the response of bone turnover markers and indices of energy status after 2 weeks of oral contraceptive (OC) therapy in premenopausal women with exercise-associated menstrual disturbances (EAMD). Six women with EAMD received one 28-day cycle of a triphasic
Susan Jick et al.
Contraception, 76(1), 4-7 (2007-06-26)
In 2006, we published a study that indicated that the new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin did not increase the risk for venous thromboembolism (VTE) compared to oral contraceptive containing norgestimate and 35 microg
Ronald T Burkman et al.
Contraception, 79(6), 424-427 (2009-05-16)
This analysis investigated the association of oral contraceptive efficacy with body weight and body mass index (BMI) for hypothesis-generating purposes. Data were from a randomized, parallel-group trial of 180/215/250 mcg of norgestimate (NGM)/25 mcg of ethinyl estradiol (EE) (given to
Julia V Johnson et al.
Obstetrics and gynecology, 111(2 Pt 1), 278-284 (2008-02-02)
To compare the effects of oral and transdermal contraceptives containing similar hormone formulations on vascular risk markers. We conducted a randomized, investigator-blinded, crossover, clinical trial with 24 healthy women, aged 18-35 years, who received 2 months of transdermal or oral
Teri Greco et al.
Contraception, 76(1), 8-17 (2007-06-26)
This study compared two oral contraceptives (OCs) with the same triphasic regimen of progestin (norgestimate 0.18, 0.215 and 0.25 mg) but differing doses of ethinyl estradiol (EE) - 25 and 35 microg EE - in their effects on androgens, mood

Articles

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service